← Back to all trials
Active Not Recruiting
NCT06508749
The Tatelo Plus Study
Conditions: HIV, HIV Infections
Sex: All
Ages: 24 Weeks – 25 Years
Healthy volunteers: No
Phase: PHASE1, PHASE2
Enrollment: 41
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Location: Francistown CRS (CRS #31891) Francistown
Summary
The purpose of this study is to advance pediatric HIV treatment and cure research by evaluating the impact of a combination of three anti-HIV-1 broadly neutralizing antibodies (bNAbs) or analytic treatment interruption (ATI) on viral reservoir, immune function, and maintenance of HIV suppression in early-treated children.
Eligibility Criteria
Inclusion Criteria, Step 1
* Previously enrolled in the EIT/Tatelo, or Moso Cohort Study
* Receiving prescribed ART for at least 24 weeks prior to study entry as determined by the site investigator based on participant/parent/guardian report and available medical records
* 24 weeks to 12 years of age at enrollment, inclusive
* If entering Step 1a: HIV-1 RNA \
Source: ClinicalTrials.gov (NCT06508749). StuddyBuddy aggregates publicly available trial information.
